Zoetis Unveils 2024 Sustainability Progress Report, Showcasing Global Commitments to Communities, Animal Health, and the Planet Zoetis, a global leader in animal health, has released its 2024 Sustainability Progress Update,…
Sanofi Unveils 2025 Global Employee Shareholding Plan, Reinforcing Long-Term Workforce Commitment Sanofi has officially launched Action 2025, the latest installment of its long-running global employee shareholder program. Opening on June…
Vividion and Bayer Expand Oncology Pipeline with Exclusive Rights to Clinical-Stage WRN Inhibitor VVD-214 Vividion Therapeutics,a clinical-stage biopharmaceutical company and wholly owned subsidiary of Bayer AG, has announced a significant…
CPR Training Turns Walgreens Manager into a Hero Dad: How Quick Thinking Saved His Daughter’s Life Adyn Romahn was enjoying a quiet moment at home in Great Bend, Kansas, watching…
Neglected Again: ODA Cuts Threaten Global Progress on Tropical Diseases Neglected tropical diseases (NTDs) continue to plague over a billion people around the world, predominantly affecting vulnerable populations in low-resource…
Global Drive for Primary Health Care Gains Ground at World Health Assembly: A Unified Call to Action In a powerful demonstration of international unity and purpose, global health leaders convened…
Legend Biotech Unveils Landmark Five-Year Survival Data for CARVYKTI® in Relapsed/Refractory Multiple Myeloma at ASCO 2025 Legend Biotech Corporation,a global leader in cell therapy innovation, presented groundbreaking long-term data at…
Bayer’s Nubeqa Secures Third FDA Approval, Expanding Prostate Cancer Treatment Landscape Bayer has announced that the U.S. Food and Drug Administration (FDA) has granted approval for a third indication of…
Takeda Secures European Commission Approval for ADCETRIS® in Combination with ECADD as a New Frontline Therapy for Adults with Advanced-Stage Hodgkin Lymphoma Takeda has announced a major milestone in the…
ASCO 2025: Subcutaneous Sarclisa with On-Body Injector Shows Promise in Multiple Myeloma Treatment At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Sanofi presented promising data from two…
AbbVie Launches Second Annual Migraine Career Catalyst Award to Empower People with Migraine in Pursuit of Their Professional Dreams Pharmaceutical company AbbVie has announced the return of its AbbVie Migraine…
Roche Announces Positive Phase III IMforte Study Results: Tecentriq Combined with Lurbinectedin Demonstrates Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer Roche today reported promising outcomes from the pivotal…